posted on 2013-12-06, 00:00authored byDenys T. Lau, Nathaniel D. Mercaldo, Joseph W. Shega, Alfred Rademaker, Sandra Weintraub
This study provides empirical evidence on whether polypharmacy and potentially inappropriate prescription medications (PIRx, as defined by the 2003 Beers criteria) increase the likelihood of functional decline among community-dwelling older adults with dementia. Data were from the National Alzheimer's Coordinating Center, Uniform Data Set (9/2005-9/2009). Study sample included 1,994 community-dwelling subjects aged ≥65 with dementia at baseline. Results showed that subjects having ≥5 medications were more likely to have functional decline than subjects having <5 medications. However, the increased likelihood was only apparent in subjects who did not have PIRx. Instead of magnifying the associated risk as hypothesized, PIRx appeared to have a protective effect albeit marginally statistically significant. Therefore, increased medication burden may be associated with functional decline in community-dwelling older adults with dementia who are not prescribed with PIRx. More research is needed to understand which classes of medications have the most deleterious effect on this population.
Funding
During this study, Dr. Lau was supported in part by a K-
01 research award (K01AG027295) from the National Institute on Aging. Mr. Mercaldo
was supported in part by the National Alzheimer’s Coordinating Center under a
research grant from the National Institute on Aging (U01AG016976). Dr. Shega was
supported by a career development award sponsored by the National Palliative Care
Research Center and the National Institute on Aging (K23AG029815). Dr. Weintraub’s
and Dr. Rademaker’s roles were supported in part by Alzheimer’s Disease Core Center
Grant (AG13854) to Northwestern University (PI: Mesulam).